P Hoever

Summary

Affiliation: Actelion Pharmaceuticals Ltd
Country: Switzerland

Publications

  1. doi Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant
    P Hoever
    Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    Clin Pharmacol Ther 87:593-600. 2010
  2. pmc Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial
    P Hoever
    Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    Clin Pharmacol Ther 91:975-85. 2012

Detail Information

Publications2

  1. doi Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant
    P Hoever
    Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    Clin Pharmacol Ther 87:593-600. 2010
    ..Population pharmacokinetic/pharmacodynamic modeling suggested that doses of ~500 mg almorexant and 10 mg zolpidem are equivalent with respect to subjectively assessed alertness...
  2. pmc Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial
    P Hoever
    Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    Clin Pharmacol Ther 91:975-85. 2012
    ..placebo. Adverse-event incidence was dose-related. Almorexant consistently and dose-dependently improved sleep variables. The orexin system may offer a new treatment approach for primary insomnia...